ANL Stock

Adlai Nortye Ltd. Sponsored ADR (ANL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 (“EP4”) antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT') (“CRT”) for the treatment of rectal cancer. The study has been developed and is being led by the Cancer Research (“CRUK”) Clinical Trials Unit (“CTU”) at the University of Leeds, with clinical leadership teams from consultant oncologists Prof Simon Gollins and Prof Mark Saunders.

This is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have fared in comparison to their industry in the current year.

Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have outperformed their sector year-to-date.

The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO market looks like it will be off to a quiet start, with no IPOs currently scheduled for the week ahead.

Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning out deals. Three IPOs are currently scheduled to list in the week ahead, although other small issuers may join the calendar during the week.

Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell cancer. The global market for head and neck cancer treatments is expected to reach $3.5 billion by 2030.